🔗 Share this article World Health Organization Raises Alert Over Acute Lack of Obesity Injections Fewer than a tenth of people eligible to benefit from weight-loss injections like Wegovy are able to get them, caution the global health agency as it releases its first advice on the medications. With more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable availability to these injectable treatments. Per estimates, more than two billion could be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and ongoing care," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major obstacles to widespread availability to the injections that can help people shift significant body mass, explains the agency. Skinny Jab Shortage Even in the current most favorable scenario, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of the global need, as stated by the WHO. The recommendation urges governments and firms to expand availability, by strategies like patent sharing. The intellectual property rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Operate GLP-1 drugs mimick a body's own hormone to slow digestion, curb appetite and increase feelings of fullness so individuals eat less. Patients usually see weight reduction in the initial weeks of starting on the once-weekly jabs. Evidence suggests patients may regain a significant portion a year later of stopping the treatment, because their normal appetite resume. To be above a healthy weight increases your risk for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies. Excess weight impacts people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
Fewer than a tenth of people eligible to benefit from weight-loss injections like Wegovy are able to get them, caution the global health agency as it releases its first advice on the medications. With more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable availability to these injectable treatments. Per estimates, more than two billion could be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and ongoing care," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major obstacles to widespread availability to the injections that can help people shift significant body mass, explains the agency. Skinny Jab Shortage Even in the current most favorable scenario, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of the global need, as stated by the WHO. The recommendation urges governments and firms to expand availability, by strategies like patent sharing. The intellectual property rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Operate GLP-1 drugs mimick a body's own hormone to slow digestion, curb appetite and increase feelings of fullness so individuals eat less. Patients usually see weight reduction in the initial weeks of starting on the once-weekly jabs. Evidence suggests patients may regain a significant portion a year later of stopping the treatment, because their normal appetite resume. To be above a healthy weight increases your risk for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies. Excess weight impacts people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.